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Abstract:  Several  factors  have  been  proposed  to explain  the persistence  of  a  high  incidence  of 
venous thromboembolism worldwide with its associated morbidity and mortality. Underutilization 
of anticoagulants and failure of adherence to thromboprophylaxis guidelines 
health concerns. We herein review this alarming observation with special emphasis on the Middle 
East region. We also discuss strategies that could help control this increasingly reported problem.
Introduction:  It  is  well  established  that  venous 
thromboembolism  (VTE)  is  the  most  common 
preventable  cause  of  death  in  the  hospital  setting, 
accounting  for  5-10%  of  fatalities.
1
VTE  is  not  restricted  to  the  inpatient  setting  with 
several studies showing VTE frequently occurring post 
hospital  discharge.
5-7 Despite  the  existence  of 
guidelines for VTE  prophylaxis  in  both  medical and 
surgical patients,
8 medical centers worldwide continue 
to show elevated incidence rates of VTE.
be  attributed  to  a  significant  gap  between  actual 
clinical practice and recommendations.
will highlight this alarming problem with emphasis on 
the Middle East region.
Results  from  The  ENDORSE  Study
Epidemiologic International Day for the Evaluation of 
Patients at Risk for VTE in the Acute Hospital Care 
Setting  (ENDORSE)  study  was  a  cross
pen Journal System 
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Several  factors  have  been  proposed  to explain  the persistence  of  a  high  incidence  of 
venous thromboembolism worldwide with its associated morbidity and mortality. Underutilization 
of anticoagulants and failure of adherence to thromboprophylaxis guidelines 
health concerns. We herein review this alarming observation with special emphasis on the Middle 
East region. We also discuss strategies that could help control this increasingly reported problem.
It  is  well  established  that  venous 
thromboembolism  (VTE)  is  the  most  common 
preventable  cause  of  death  in  the  hospital  setting, 
1-4 Furthermore, 
VTE  is  not  restricted  to  the  inpatient  setting  with 
several studies showing VTE frequently occurring post 
Despite  the  existence  of 
guidelines for VTE  prophylaxis  in  both  medical and 
medical centers worldwide continue 
TE.
1,9-12 This may 
be  attributed  to  a  significant  gap  between  actual 
clinical practice and recommendations.
13-14 This review 
will highlight this alarming problem with emphasis on 
Results  from  The  ENDORSE  Study:  The 
Epidemiologic International Day for the Evaluation of 
Patients at Risk for VTE in the Acute Hospital Care 
y  was  a  cross-sectional 
survey  that  assessed  the  adherence  to  the  guidelines 
across 32 countries in 5 continents.
considerable  variation  among  countries,  with 
adherence to guidelines ranging from 0.2% to 92% for 
surgical patients and 3% to 70% for medical patients. 
The  2004  American  College  of  Chest  Physicians 
(ACCP)  guidelines  were used  to  stratify patients  for 
VTE risk and need for anticoagulation.
The compliance with the ACCP guidelines was only 
assessed in terms of the type of prophylaxis used, with 
dosing and duration not taken into account because 
the  differences  in  dosing  recommendations  across 
countries, and because of the cross
the study.
14 According to the study, the most common 
VTE  risk factors  are  chronic pulmonary  disease  and 
chronic heart failure for medical patients, and obesity 
for  surgical  patients.
14
immobilization  (immobilization  with  bathroom 
privileges),  and  admission  to  an  intensive  care  unit 
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Several  factors  have  been  proposed  to explain  the persistence  of  a  high  incidence  of 
venous thromboembolism worldwide with its associated morbidity and mortality. Underutilization 
of anticoagulants and failure of adherence to thromboprophylaxis guidelines are emerging global 
health concerns. We herein review this alarming observation with special emphasis on the Middle 
East region. We also discuss strategies that could help control this increasingly reported problem.
survey  that  assessed  the  adherence  to  the  guidelines 
across 32 countries in 5 continents.
14 The study showed 
considerable  variation  among  countries,  with 
adherence to guidelines ranging from 0.2% to 92% for 
surgical patients and 3% to 70% for medical patients. 
04  American  College  of  Chest  Physicians 
(ACCP)  guidelines  were used  to  stratify patients  for 
VTE risk and need for anticoagulation.
14
The compliance with the ACCP guidelines was only 
assessed in terms of the type of prophylaxis used, with 
dosing and duration not taken into account because of 
the  differences  in  dosing  recommendations  across 
countries, and because of the cross-sectional nature of 
According to the study, the most common 
VTE  risk factors  are  chronic pulmonary  disease  and 
chronic heart failure for medical patients, and obesity 
Complete  and  partial 
tion  (immobilization  with  bathroom 
privileges),  and  admission  to  an  intensive  care  unit Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
were the most common risk factors for post-discharge 
VTE in both medical and surgical patients.
14
Five  Middle  Eastern  countries  participated  in  the 
study: Egypt, Kuwait, Saudi Arabia, Turkey, and the 
United  Arab  Emirates,  collectively  showing  a 
guideline-adherence  rate  of  38%.
14 In  comparison, 
other  geographical  regions  in  the  study  showed  the 
following guideline-adherence rates: America (Brazil, 
Columbia, Mexico, USA, and Venezuela) 56%, Asia 
(Bangladesh,  India,  Pakistan,  and  Thailand)  9%, 
Europe (Bulgaria, Czech Republic, France, Germany, 
Greece, Hungary, Ireland, Poland, Portugal, Romania, 
Russia,  Slovakia,  Spain,  Switzerland,  and  the  UK) 
56%, North Africa (Algeria and Tunisia) and Oceania 
(Australia) 46% and 57%, respectively. Globally, the 
study  showed  that  50%  of  all  patients  at-risk  were 
receiving the ACCP recommended prophylaxis.
14
The ENDORSE study grouped patients according to 
whether they were medical or surgical cases. Medical 
patients were stratified based on the medical condition, 
and surgical patients based on the type of surgery they 
were undergoing.
14 It was shown that surgical patients 
received  higher  rates  of  recommended  prophylaxis 
(59%)  compared  to  medical  patients  (40%).  The 
discrepancy  in  rates  was  significant  in  all  regions 
except  the  Middle  East,  with  medical  and  surgical 
guideline  adherence  rates  being  38%  and  39%, 
respectively (Table1). 
Finally,  the  ENDORSE  study  also  reported  the 
percentages  of  patients  that  received  some  form  of 
prophylaxis  irrespective  of  whether  it  followed  the 
risk-stratification guideline of the ACCP. In the Middle 
East  region, 45%  of  patients received  some form of 
prophylaxis  (41%  medical,  48%  surgical),  with  the 
other  regions  performing  as  follows:  America  67% 
(63% medical, 71% surgical), Asia 11% (14% medical, 
9%  surgical),  Europe  62%  (49%  medical,  71% 
surgical),  North  Africa  48%  (31%  medical,  72% 
surgical),  and  Oceania  66%  (51%  medical,  82% 
surgical).
14
Results from the AVAIL ME Study: The Assessment 
for VTE Management in Hospitals in the Middle East 
(AVAIL  ME)  study  was  the first comprehensive
Table 1. Adherence to guidelines in medical and surgical patients 
across regions evaluated by the ENDORSE study.
Region Medical Surgical
America 49% 63%
Asia 12% 7%
Europe 41% 67%
Middle East 38% 39%
North Africa 28% 71%
Oceania 42% 72%
evaluation  of  VTE  prophylaxis  in  the  Middle  East 
region. It was conducted to properly evaluate the status 
of anticoagulation practices in the Middle East and to 
serve  as  a  foundation  for  attempts  at  quality 
improvement.
15 The study included countries from the 
Middle  East  (Kingdom  of  Saudi  Arabia,  Lebanon, 
Syria,  and  United  Arab  Emirates),  and  from  Central 
Asia  (Georgia,  Iran,  and  Kazakhstan).
15 Previous 
studies on VTE prophylaxis in the Middle East were 
performed  on  diverse  populations,  across  different 
timelines,  employed  varied  methodologies,  and  were 
limited  to  predefined  specialties  (orthopedics, 
gynecology,  etc),  which  made  them  unsuitable  for 
adequate comparison.
15
The  study  showed  consistently  lower  rates  of 
adherence to the guidelines in the Middle East region 
compared  to  global  figures,  thereby  confirming  the 
findings  of  the  ENDORSE  study.
15 Moreover,  the 
study  underlined  the  inappropriate  utilization  of 
prophylaxis  in  the  Middle  East  in  patients  with 
contraindications, further emphasizing the divergence 
from the guidelines compared to the other regions.
16
The study showed that 54.9% of patients received 
drug  prophylaxis  for  VTE,  but  that  only  36.9% 
received  the  2004  ACCP  recommended  prophylaxis 
according to risk (the most up-to-date guidelines at the 
time of data collection).
15 Of the 2,266 patients in the 
study, 82.9% were eligible for prophylaxis according 
to the guidelines. 51.2% obtained some form of VTE 
prophylaxis, but only 37.8% according to the ACCP. 
50.1%  of  eligible  patients  received  drug  prophylaxis 
(90.2%  low  molecular  weight  heparin,  10.7% 
unfractionated  heparin,  1.5%  vitamin  K  antagonists, 
and  0.1% fondaparinux),  16.4%  received  mechanical 
prophylaxis (graduated compression stockings in 97% 
of  cases),  15.3%  received  both  modalities,  and  the 
remaining received no prophylaxis.
15
Stratification  into  risk  groups  revealed  that 
guideline application was observed in 86.3%, 41.1%, 
48.3%, and 24.5% in the low, moderate, high, and very 
high-risk groups respectively. Concurrently, some form 
of VTE prophylaxis was given to 17.9% of the low-risk 
patients,  and  in  41.7%,  60.6%,  and  66.9%  of  the 
moderate,  high,  and  very  high-risk  groups, 
respectively.
15
The  Kappa  coefficient  was  calculated  to  evaluate 
concordance between eligibility for VTE prophylaxis 
and drug application, both according to guidelines, and 
was found to be equal to 0.16 (it ranges between 0 = no 
concordance,  and  1  =  perfect  concordance)  with  a 
statistically significant P < 0.001. The study revealed 
that  45.1%  of  patients  who  should  have  received 
prophylaxis did not, and 26.9% of patients who were 
not  eligible  for  prophylaxis  did  receive  it.  Separate 
Kappa  values  were  also  calculated  after  risk-Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
stratification  with  values  of  0.09  for  moderate-risk, 
0.20 for high-risk, and 0.09 for very high-risk patients 
(all statistically significant). Concordance for low-risk 
patients cannot be calculated because they should not 
receive prophylaxis.
15
In the same study, it was observed that there were 
significant differences in adherence depending on the 
medical  condition,  with  40.2%  of  patients  with 
ischemic stroke, 38.8% of cancer patients, and 35.7% 
of patients with heart failure (NYHA class III or IV) 
receiving  prophylaxis  according  to  the  guidelines 
compared to only 26.7% of patients with hemorrhagic 
stroke and 26.8% of patients with renal failure
15. This 
discrepancy in the use of prophylaxis among different 
medical conditions was also found in a previous study 
in Lebanon which showed higher prophylaxis rates in 
intensive  care  unit  patients  (62.5%)  compared  to 
patients admitted for malignancies (17.7%).
17
In addition to the AVAIL ME study, several studies 
continue  to  show  discordance  in  the  Middle  East 
between  VTE  prophylaxis  and  the  guidelines.
18-19
These figures are more pronounced given the elevated 
proportion of the high-risk group in the region.
15 The 
observation that  medical patients  in  the  Middle East 
region  receive  less  drug  prevention  than  surgical 
patients is congruent with the results of other regional 
studies.
20-23 These  results continue  to  emerge despite 
the finding that more than 70% of VTE events occur in 
medical  patients  compared  to  only  30%  or  less  in 
surgical patients.
12,24-25
Towards  More  than  an  Ounce  of  Prevention: 
Inappropriate  thromboprophylaxis is  a  substantial 
problem  that  requires  immediate  attention.  Efforts 
should be made to systematically assess patients at risk 
for  VTE  using  practical models,  urgently implement 
hospital-wide  strategies,  and  provide  appropriate 
prophylaxis  to  prevent  this  common  and  avoidable 
disease. This remains essential in developing countries 
with  limited  health  care  resources.  Educational 
sessions targeting practicing physicians and staff and 
efforts towards changing guidelines to hospital policy 
should also ensue. 
Several VTE risk assessment models (RAMs) and 
algorithms have been suggested.
20,26-31 However, most 
of these RAMs have not been prospectively validated, 
and the only two validated models present limitations 
that  preclude  widespread  implementation.
30-31 The 
adoption of electronic tools was found to be effective 
in encouraging physicians to use prophylaxis at least 
amongst  subgroups  of  patients  at  high-risk  of 
thrombotic  complications.
30-31 The  electronic  alerting 
systems,  however,  require  sophisticated  technology 
infrastructure and considerable financial resources, and 
are thus unlikely to find widespread acceptance across 
the  many  institutions  that  admit  patients  at  risk  of 
thrombosis.  Self-explanatory,  easy,  suitable  and 
effective  RAMs  may  have  the  potential  to  help 
physicians manage their patients without the need for 
supplementary electronic tools, and may result  in  an 
increasing  implementation  of  antithrombotic 
prophylaxis, in compliance with the recommendations 
of  the  main  international  guidelines  and  with  the 
auspices of several world health organizations. A new 
simple  points  score  system,  the  Padua  Prediction 
Score,
32 was  recently  reported.  The  system  was 
evaluated  for  its  potential  to  detect  hospitalized 
medical patients at high-risk for developing VTE, and 
its  value  was  prospectively  assessed  in  a  broad 
spectrum  of  consecutive  patients  admitted  to  an 
Internal  Medicine  ward  in  a  two-year  period.  All 
patients  included  in  the  study  were  prospectively 
followed-up for up to three months after admission in 
order to assess the incidence of symptomatic VTE. The 
simple  20-point  RAM  adopted  clearly  discriminated 
between  hospitalized  medical  patients  at  high- and 
low-risk of VTE complications. The implementation of 
in-hospital thromboprophylaxis in patients classified as 
being at high-risk of thrombosis according to this RAM 
was  highly  effective,  and  was  associated  with  an 
acceptably low-risk of bleeding. However, this benefit 
of  this  model  needs  to  be  prospectively  evaluated.
Following pilot results of the AVAIL ME study, the
alarming  gap in  adherence  to  practice guidelines  led 
most  involved  centres,  and  many  others,  to  start 
initiatives of careful planning to control the problem. 
Educational  sessions  targeting  practicing  physicians 
and  staff  and  efforts  towards  changing  guidelines  to 
hospital  policy  ensued.  These  efforts  are  to  be 
prospectively evaluated to  determine their impact  on 
the problem currently at hand. 
Conclusions: The Middle East region has consistently 
lower  rates  of  adherence  to  VTE  prophylaxis 
guidelines, in  both medical  and surgical populations, 
compared to other regions. These shortcomings need to 
be  addressed  with  outmost  importance  given  the 
preventable  nature  of  VTE,  and  the  potential  to 
substantially  decrease  associated  morbidity  and 
mortality in the region. 
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